One To Watch

Alnylam Pharmaceuticals

A commercial-stage biopharmaceutical company, Alnylam Pharmaceuticals is built around RNA interference therapeutics and is scaling a global medicines business across rare diseases, transthyretin amyloidosis, and broader cardiometabolic, neuroscience, and hematology programs.

Headquarters and Global Presence

Alnylam is headquartered in Cambridge, Massachusetts. Although rooted in the United States, it operates as a global company with marketed products, development activities, and partner-supported commercialization spanning multiple major markets, including Europe, Japan, Latin America, and other international territories.

Founding and History

Alnylam was founded in 2002 by researchers and biotech leaders seeking to translate RNA interference into medicines. Its first commercial product was approved in 2018, marking the first RNAi therapeutic to reach the market, and the company has since expanded into a multi-product commercial business while remaining heavily research-driven. Its more recent evolution has been defined by the build-out of a broader commercial platform and the launch of its Alnylam 2030 strategy.

Therapy Areas and Focus

Alnylam remains strongly associated with rare disease, especially transthyretin amyloidosis, acute hepatic porphyria, and primary hyperoxaluria type 1. At the same time, it is moving beyond its original orphan-disease concentration into larger cardiovascular, metabolic, neuroscience, and hematology opportunities, making it a broader RNAi medicines company rather than a niche rare disease specialist alone.

Technology Platforms and Modalities

Alnylam develops small interfering RNA therapeutics that silence disease-causing genes by harnessing the natural RNA interference pathway. Its technical differentiation rests on RNAi chemistry, delivery platforms, and manufacturing capabilities designed to enable durable gene silencing in liver and extrahepatic tissues, supporting both rare disease medicines and expansion into larger chronic indications.

Key Pipeline and Programs

Alnylam is already a commercial-stage company with approved products including AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO, while partner-commercialized products include Leqvio and Qfitlia. The company’s strategic center of gravity is now its growing transthyretin franchise, led by AMVUTTRA and supported by Phase III nucresiran, alongside later-stage partnered or proprietary programs such as zilebesiran in hypertension, cemdisiran in complement-mediated disease, ALN-6400 in bleeding disorders, and mivelsiran in cerebral amyloid angiopathy and Alzheimer’s disease.

Key Personnel

Yvonne Greenstreet, MD, MBA, OBE, serves as chief executive officer and has led the company since January 2022. Amy W. Schulman is chair of the board, and the broader leadership team reflects Alnylam’s mix of commercial execution, platform science, and late-stage drug development experience.

Strategic Partnerships

Alnylam uses partnerships selectively to extend the reach of its RNAi platform while retaining a growing proprietary commercial base. Important relationships include Novartis for inclisiran, Sanofi for fitusiran, Roche for zilebesiran, and Regeneron across complement-related and other programs, even as Alnylam increasingly emphasizes its wholly controlled franchises and internal commercialization capabilities.

FAQ Section

The central issue is whether Alnylam can turn its early RNAi leadership into durable scale by extending beyond rare disease into larger markets without losing capital discipline or pipeline productivity. Its success now depends on balancing commercial execution in ATTR amyloidosis with continued clinical validation in broader disease areas.

RNA interference matters because it targets disease at the level of gene expression, allowing Alnylam to reduce production of proteins that drive pathology rather than only modulating downstream effects. That creates the possibility of durable and mechanistically precise treatments across both rare and prevalent diseases.

Alnylam is differentiated by having turned RNAi from a scientific concept into a repeatable commercial and development model with multiple approved products. Unlike many platform companies, it now combines modality leadership with a real global product business and a deep clinical pipeline.

AMVUTTRA is important because it anchors Alnylam’s transthyretin franchise and is the company’s main growth driver following its expansion into ATTR amyloidosis with cardiomyopathy. It also represents the clearest proof that Alnylam can scale RNAi into large commercial markets.

The pipeline spans rare diseases, transthyretin amyloidosis, cardiovascular disease, metabolic disease, neuroscience, hematology, and selected additional specialty indications. Rare disease and cardio-vascular disease are the clearest anchors of the current strategy.

Alnylam is a commercial-stage biotechnology company with multiple approved medicines and a large clinical pipeline. It is no longer a platform-stage or development-stage business, although platform innovation remains central to its model.

Key watchpoints include the long-term durability of the AMVUTTRA-led transthyretin franchise, Phase III progress for nucresiran and zilebesiran, the development trajectory of mivelsiran and ALN-6400, and whether newer extrahepatic programs can broaden the platform beyond liver-based applications. Investors will also watch how effectively Alnylam converts pipeline breadth into profitable growth under its Alnylam 2030 strategy.

Want to Update your Company's Profile?